AXON - Axovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.825
-0.075 (-2.59%)
As of 3:39PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.900
Open2.920
Bid2.830 x 2200
Ask2.840 x 1200
Day's Range2.800 - 3.000
52 Week Range1.020 - 27.976
Volume2,234,392
Avg. Volume5,320,695
Market Cap344.859M
Beta-0.12
PE Ratio (TTM)N/A
EPS (TTM)-2.064
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.14
Trade prices are not sourced from all markets
  • Here's Why Axovant Sciences Fell as Much as 21.3% Today
    Motley Foolyesterday

    Here's Why Axovant Sciences Fell as Much as 21.3% Today

    The meteoric rise in recent weeks is proving unsustainable.

  • GlobeNewswire2 days ago

    Axovant to Present at First Annual Roivant Pipeline Day

    Axovant Sciences (AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET. A live webcast will be available in the Investors section of Axovant's website at www.axovant.com. Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.

  • Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
    Zacks7 days ago

    Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

    Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

  • A Look at Axovant Sciences’ Therapy for Parkinson’s Disease
    Market Realist7 days ago

    A Look at Axovant Sciences’ Therapy for Parkinson’s Disease

    Axovant Sciences (AXON) and Oxford Biomedical aim to develop AXO-Lenti-PD gene therapy as a long-term treatment for PD (Parkinson’s disease). Once administered using MRI1-guided stereotactic delivery, this gene therapy could help reduce motor fluctuations resulting from depleting dopamine levels in the brain.

  • Why Axovant Sciences Stock Is Soaring
    Market Realist7 days ago

    Why Axovant Sciences Stock Is Soaring

    Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80, largely due to the company’s entry into lentiviral vector gene therapy for PD (Parkinson’s disease) through a licensing arrangement with Oxford BioMedica. Axovant Sciences has secured worldwide development and commercialization rights for its investigational therapy, AXO-Lenti-PD, which aims to restore dopamine in the striatum of PD patients’ brain.

  • Why Xunlei, Griffon, and Axovant Sciences Slumped Today
    Motley Fool8 days ago

    Why Xunlei, Griffon, and Axovant Sciences Slumped Today

    Find out why these stocks got smacked down the hardest.

  • Why Axovant Sciences Stock Rose in Week Ended June 8
    Market Realist8 days ago

    Why Axovant Sciences Stock Rose in Week Ended June 8

    Axovant Sciences (AXON) stock rose 150% in the week of June 1–8. Over the last quarter, Axovant Sciences stock has risen 192.7%. On June 6, Axovant Sciences entered into a licensing agreement for worldwide rights to develop and sell Oxford BioMedica’s OXB-102 investigational gene therapy for the treatment of Parkinson’s disease.

  • What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month
    InvestorPlace9 days ago

    What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month

    As a micro-cap company, Axovant Sciences Ltd (NASDAQ:AXON) is naturally fraught with risks. The company is losing money and debt levels are elevated at 0.49 times equity. AXO-Lenti-PD is a gene therapy for treating Parkinson’s disease.

  • Implied Volatility Surging for Axovant (AXON) Stock Options
    Zacks9 days ago

    Implied Volatility Surging for Axovant (AXON) Stock Options

    Axovant (AXON) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher
    Zacks9 days ago

    Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher

    Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares rise nearly 9% on the day.

  • Breakeven On The Horizon For Axovant Sciences Ltd (NASDAQ:AXON)
    Simply Wall St.11 days ago

    Breakeven On The Horizon For Axovant Sciences Ltd (NASDAQ:AXON)

    Axovant Sciences Ltd’s (NASDAQ:AXON): Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United StatesRead More...

  • 3 Drug Stocks That Soared This Week: Are They Buys?
    Motley Fool11 days ago

    3 Drug Stocks That Soared This Week: Are They Buys?

    Can these red-hot drug stocks keep the momentum going?

  • Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session
    Zacks12 days ago

    Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session

    Axovant Sciences (AXON) shares rose nearly 6% in the last trading session, amid huge volumes.

  • $842M gene therapy deal to boost development by Roivant spinoff in Durham
    American City Business Journals12 days ago

    $842M gene therapy deal to boost development by Roivant spinoff in Durham

    After an organizational restructuring that followed the announcement of negative Phase 3 trial results for a drug being developed as a therapy for Alzheimer’s disease, Roivant spinoff Axovant has inked an $842 million gene therapy deal expected to boost development out of Durham.

  • See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
    Markit12 days ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Axovant Sciences Ltd NASDAQ/NGS:AXON

  • ACCESSWIRE12 days ago

    Wired News – Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinson’s Treatment

    LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Axovant Sciences Ltd (NASDAQ: AXON) ("Axovant"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AXON as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has signed an exclusive worldwide licensing deal with Oxford BioMedica to develop and commercialize OXB-102 (now AXO-Lenti-PD), a gene therapy developed by Oxford BioMedica for Parkinson's disease utilizing the LentiVector® platform. Active-Investors.com is currently working on the research report for ProQR Therapeutics N.V. (NASDAQ: PRQR), which also belongs to the Healthcare sector as the Company Axovant Sciences.

  • Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica
    Zacks13 days ago

    Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica

    Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.

  • Why Camping World Holdings, Axovant Sciences, and Sonic Jumped Today
    Motley Fool13 days ago

    Why Camping World Holdings, Axovant Sciences, and Sonic Jumped Today

    Find out what tasty news one restaurant chain offered to investors.

  • Benzinga13 days ago

    Oppenheimer: Axovant Deal Transform Pipeline

    Axovant Sciences Ltd (NASDAQ: AXON ) announced Wednesday that it licensed global rights to Oxford BioMedica’s investigational gene therapy for Parkinson’s Disease. As some experts see it, the drug could ...

  • Here's Why Axovant Sciences Stock Skyrocketed Today
    Motley Fool13 days ago

    Here's Why Axovant Sciences Stock Skyrocketed Today

    Can the company treat Parkinson's disease with gene therapy?

  • TheStreet.com13 days ago

    These Stocks Are Leading the Nasdaq's Record-Setting Push

    For three straight sessions, the tech-heavy index has set record closing highs even as its fellow major stock indexes have moved in and out of the green. While Nasdaq's record streak was in jeopardy early Thursday, June 7, these stocks have been leading the index's push higher. shares have risen 5.75% over the past five sessions.

  • Why Axovant Sciences Stock Jumped ~160% on Wednesday
    Market Realist13 days ago

    Why Axovant Sciences Stock Jumped ~160% on Wednesday

    Axovant Sciences (AXON) is a clinical-stage biopharmaceutical company. The company’s stock price jumped ~160.0% to the closing price of $4.55 on June 6 due to several factors. Axovant Sciences stock price has increased by ~137.0% in the last three trading sessions.

  • ACCESSWIRE13 days ago

    Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics

    NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Axovant Sciences was one of the biggest gainers in the stock market on Wednesday after announcing that it has licensed an investigational gene therapy for Parkinson's Disease from Oxford BioMedica. Shares of Heat Biologics also climbed a lot higher despite any news. The company's CEO was said to present at the 2018 BIO International Convention on Wednesday.

  • ACCESSWIRE13 days ago

    57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS

    Cell and gene therapy development hitting fever pitch globally as more products enter phase 3 and late-stage testing. Growing their sales consistently, and partnered with high-profile public clients, ORGS could be significantly undervalued with continued executiona and expansion. NEW YORK, NY / ACCESSWIRE / June 7, 2018 / The curative potential of gene and cell therapies has kept these new pharmaceutical products front and center for healthcare investors for the last 3 years.

  • Gene Therapy Deal Helps Double Price of Beaten-Down Biotech Company's Shares
    Bloomberg14 days ago

    Gene Therapy Deal Helps Double Price of Beaten-Down Biotech Company's Shares

    Axovant Sciences Ltd. investors are enjoying their first rays of light in months as the shares more than doubled on the company’s plan to license a gene therapy from Oxford BioMedica Plc. Axovant agreed to pay the U.K.-listed company $30 million upfront in cash for rights to develop OXB-102 for Parkinson’s disease. Oxford could get an additional $812.5 million if certain development and sales milestones are reached.